Oramed Pharmaceuticals (ORMP) Payables (2011 - 2026)

Oramed Pharmaceuticals has reported Payables for 16 years, with the latest figure at $8.8 million in Q1 2026.

• For the quarter ending Q1 2026, Payables rose 1633.6% year-over-year to $8.8 million; the trailing twelve-month figure through Mar 2026 stood at $8.8 million (up 1633.6% YoY), and the FY2025 full-year result was $7.1 million, up 537.57% from the prior year.
• Payables for Q1 2026 stood at $8.8 million, up from $7.1 million in the prior quarter.
• The five-year high for Payables was $77.9 million in Q3 2023, with the low at $509000.0 in Q1 2025.
• Historically, Payables has averaged $9.6 million across 5 years, with a median of $4.1 million in 2023.
• Annual changes were most pronounced in 2023 — Payables soared 1722.78% — and 2025, when it tumbled 98.47%.
• Oramed Pharmaceuticals' Payables stood at $4.2 million in 2022, then sank by 78.94% to $876000.0 in 2023, then grew by 27.63% to $1.1 million in 2024, then surged by 537.57% to $7.1 million in 2025, then grew by 23.79% to $8.8 million in 2026.
• The last three Payables figures came in at $8.8 million (Q1 2026), $7.1 million (Q4 2025), and $4.9 million (Q3 2025), per Business Quant data.